TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03590353

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual Chamber Pacemaker
Description: 1. Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. 2.Putting 2 sheathing canals into heart along with guiding wires. 3.Locating the sheathing canals, and putting electrodes into canals. 3.Adjusting the electrodes and revolving them anticlockwise to lead them to right atrium and right ventricle respectively under the X-ray. 4.Immobilizing electrodes. 5. Some ways to determine whether the electrode is fixed or not: the head of the electrodes could beat rhythmically with atrium or ventricle or by testing damage current. 6.Removing the canals and suturing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: His Bundle Pacemaker
Description: 1.Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. One of the guide wire is 120cm in length, 0.035 or 0.038 in diameter, which is required to lead the C315 sheathing canal. 2.Putting C315 sheathing canal into heart along with guiding wires. 3.Locating the C315 sheathing canal, and adjusting the head of C315 towards ideal pacing location. 3.Implanting the spiral electrodes and fixing them. Leading the spiral electrode to the side of his bundle along the C315 canal under the X-ray. The other electrode is leaded to right atrium like dual chamber pacemaker under the X-ray. 4.Revolving the 3830 electrode suitably to Immobilizing it in cardiac muscle. If the electrode can get his electric potential and produce his bundle pacing successfully, we revolve the 3830 electrode and immobilize it.
Study: NCT01206582

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hemin
Description: 10 iv infusions for 8 weeks
Study: NCT01308190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine (Xeloda)
Description: Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 50.4 Gy
Description: Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transanal Endoscopic Microsurgery
Description: 6-8 weeks after Chemoradiotherapy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total Mesorectal Excision
Description: Standard surgical treatment of T2 , T3s, N0, M0 rectal cancer. Early after diagnosis
Study: NCT01381861

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Carotuximab (TRC105)
Description: Carotuximab (TRC105) 10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
Study: NCT03155009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: 600 mg orally BID with food
Study: NCT00554671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm driven medication titration
Description: Clinical pharmacists will change medications to achieve goals in hypertension, dyslipidemia and diabetes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitoring
Description: Clinical pharmacists will monitor the progress of patients in lifestyle modification and cardiac risk factor control goals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group support
Description: Peer support are provided in the group setting
Study: NCT01206582

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Albumin
Description: 10 iv infusions for 8 weeks
Study: NCT01363661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coruno
Description: Molsidomine 16 mg tablet, per os, once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (16 mg tablet, per os; once-daily)
Study: NCT03688074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study: NCT00385138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: cangrelor bolus (30 mcg/kg) \& cangrelor infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: clopidogrel capsules (600 mg) at end of PCI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: clopidogrel capsules (600 mg) at end of PCI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo bolus & placebo infusion
Description: placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules - end of PCI
Description: Placebo capsules given at the end of PCI to mimic 600mg clopidogrel dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo capsules - end of infusion
Description: Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
Study: NCT02629822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine/lamivudine/tenofovir disoproxil fumarate
Description: FDC tablet containing MK-1439 (doravirine) 100 mg / lamivudine 300 mg / tenofovir disoproxil fumarate 300 mg taken by mouth.
Study: NCT03679624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib, 420mg orally, once daily
Study: NCT04533204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mnemonic strategy training
Description: training using mnemonic strategies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: spaced retrieval training
Description: training using spaced retrieval
Study: NCT00005803

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation
Description: Undergo autologous-allogeneic tandem hematopoietic stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study: NCT03679624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib, 420mg orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab, 16 mg/kg intravenously, weekly for 8 weeks, bi weekly for 16 weeks, then monthly for up to 19 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab, 16 mg/kg intravenously, weekly for 8 weeks, bi weekly for 16 weeks, then monthly for up to 19 months.
Study: NCT00741013

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo pill and placebo IV
Description: Placebo pill every four hours, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
Study: NCT00005803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Autologous Lymphocytes
Description: IV donor lymphocyte infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo radiotherapy
Study: NCT02301468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: (experimental- physiotherapy intervention) - will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). The same 4 trigger points will be treated during the 4 weeks. DN will be performed by locating the taut band and the trigger point. Once the trigger point is located, the overlying skin will be cleaned with alcohol. A certified and experienced therapist will penetrate the needle through the skin 10-15mm. into the TrP until the local twitch response will be obtained.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic Compression
Description: (experimental - physiotherapy intervention) will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). IC will be performed by applying a pressure with a wooden stick on the 4 individually determined most painful trigger points. The duration of the pressure will be about 60s, (increase of pressure 10N/s) until the highest tolerable pressure will be reached and this pressure will be held even when the pain is decreasing during the intervention. The subject will always be treated by the same clinician.
Study: NCT04278846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depofoam bupivacaine
Description: The study drug Depofoam bupivacaine will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrochloride (HCl)
Description: The study drug bupivacaine HCl will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.
Study: NCT04115202

Intervention type: PROCEDURE
Intervention: lumbar arthrodesis
Description: two approaches anterior versus posterior, optimally by leaving physicians free to use them as they do daily without modifying their procedures

Intervention type: PROCEDURE
Intervention: lumbar arthrodesis
Description: two approaches anterior versus posterior, optimally by leaving physicians free to use them as they do daily without modifying their procedures
Study: NCT03159455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: Duration - 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Duration - 28 days
Study: NCT02366546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBI-1301
Description: TBI-1301(5\*10\^8 or 5\*10\^9) is administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBI-1301
Description: TBI-1301(5\*10\^8 or 5\*10\^9) is administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBI-1301
Description: TBI-1301(5\*10\^8 or 5\*10\^9) is administered.
Study: NCT04168593

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: 20 min of Acupuncture section follow by 10 min of cupping around the knee

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: 20 min of Acupuncture section follow by 10 min of cupping around the knee
Study: NCT03989232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Semaglutide injected subcutaneously (s.c., under the skin) once-weekly. Participants will keep taking their pre-study diabetes tablets throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide injected subcutaneously (s.c., under the skin) once-weekly. Participants will keep taking their pre-study diabetes tablets throughout the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Semaglutide placebo injected once-weekly from week 13 to week 40.
Study: NCT03213587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Study: NCT05202444

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteotomy using piezoelectrical device
Description: osteotomy were utilized using piezoelectric from device (Woodpeker) with its internal irrigation system. We used US2 tip using the maximum bone cutting program and maximum irrigation program for lateral maxillary wall osteotomy and USIR tip for the posterior maxillary wall osteotomy.~The pterygoid osteotome was placed between the tuberosity and pterygoid plates while the hamulus is palpated palatally with the index finger to guide the osteotome direction preventing palatal perforation.With the pterygoid osteotome still in position, we used a thin osteotome to complete the osteotomy of the posterior wall of the maxilla.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteotomy using piezoelectrical device
Description: osteotomy were utilized using piezoelectric from device (Woodpeker) with its internal irrigation system. We used US2 tip using the maximum bone cutting program and maximum irrigation program for lateral maxillary wall osteotomy and USIR tip for the posterior maxillary wall osteotomy.~The pterygoid osteotome was placed between the tuberosity and pterygoid plates while the hamulus is palpated palatally with the index finger to guide the osteotome direction preventing palatal perforation.With the pterygoid osteotome still in position, we used a thin osteotome to complete the osteotomy of the posterior wall of the maxilla.
Study: NCT01645241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gonadotropins plus GnRH antagonists

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganirelix
Study: NCT01473459

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVM (In Vitro Maturation) Treatment
Description: There will be no gonadotropin stimulation. There will be ovum pickup from antral follicles of immature oocyte which will be matured in the lab and fertilized by intracytoplasmic sperm injection (ICSI). Embryo transfer will take place on days 2 or 3.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF (In Vitro Fertilization) Antagonist Protocol
Description: The first stage of the treatment will be stimulation with gonadotropins. Next GNRH Antagonist will be added. Ovulation induction will be performed with GNRH agonist. After ovulation there will be ovum pickup and fertilization in the lab. Embryo transfer will take place on days 2 or 3.
Study: NCT01196286

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multifamily Group Psychoeducation (MFG)
Description: Participation in multifamily psychoeducation comprised of (i) three individual sessions with family and individual with psychosis, (ii) one psychoeducational workshop, and (iiI) twice monthly multifamily meetings to complete structured problem-solving activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifamily Group Psychoeducation (MFG)
Description: Participation in multifamily psychoeducation comprised of (i) three individual sessions with family and individual with psychosis, (ii) one psychoeducational workshop, and (iiI) twice monthly multifamily meetings to complete structured problem-solving activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Description: Computer exercises designed to improve cognitive functioning (3hr/wk).
Study: NCT01634802

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: EMR Only
Description: Clinics in this arm of the study will have a standard Electronic Medical Record (EMR) system installed - without a computerized decision support system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMR+CDSS
Description: Clinics in this arm of the study will have an Electronic Medical Record (EMR) system with Clinical Decision Support System (CDSS) enhancement implemented as alerts to aid the clinician in decision making.
Study: NCT03379597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifico (Live combined bifidobacterium,Lactobacillus and Enterococcus capsules, Oral)
Description: Bifico 840mg Bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifico (Live combined bifidobacterium,Lactobacillus and Enterococcus capsules, Oral)
Description: Bifico 840mg Bid
Study: NCT03696290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aztreonam lysine
Description: Nebulised aztreonam lysine 75mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aztreonam lysine
Description: Nebulised aztreonam lysine 75mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nebulised lactose monohydrate 5mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nebulised lactose monohydrate 5mg
Study: NCT00810147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsules, Oral, 25 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsules, Oral, 50 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsules, Oral, 100 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsules, Oral, 125 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, once daily, 24 weeks
Study: NCT03379597

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber
Description: dietary fiber compound powder 30g bid
Study: NCT00741013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin pill and placebo IV
Description: lovastatin pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo pill and recombinant human activated protein C IV
Description: placebo pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~recombinant human activated protein C IV 24 micrograms per kg per hour starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Endotoxin 4 ng/kg instilled bronchoscopically in all volunteers 12 hours after starting lovastatin treatment and 2 hours after starting recombinant human activated protein C treatment.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Endotoxin
Description: Endotoxin 4 ng/kg instilled bronchoscopically in all volunteers 12 hours after starting lovastatin treatment and 2 hours after starting recombinant human activated protein C treatment.
Study: NCT02754375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rTMS
Study: NCT00694902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK610677
Description: GSK610677 Multi-Dose Powder Inhaler will be available in the strength of 10, 50, 100 and 25 microgram with dose levels of 10, 30, 50, 100, 250, 500 and 1000 microgram. Subjects will receive GSK610677 as single inhale dose.
Study: NCT01679990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLX-PAD Low dose
Study: NCT00741013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Endotoxin 4 ng/kg instilled bronchoscopically in all volunteers 12 hours after starting lovastatin treatment and 2 hours after starting recombinant human activated protein C treatment.
Study: NCT02133781

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® 2009-2010 Formula
Description: This vaccine is given intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® 2009-2010 Formula
Description: This vaccine is given intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® 2009-2010 Formula
Description: This vaccine is given intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist® 2009-2010 Formula
Description: This vaccine is given intranasally
Study: NCT02366546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBI-1301
Description: TBI-1301(5\*10\^8 or 5\*10\^9) is administered.
Study: NCT00988273

Intervention type: DEVICE
Intervention: Confocal endomicroscopy
Description: Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the control group will be compared to the diseased group.

Intervention type: DEVICE
Intervention: Confocal endomicroscopy
Description: Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the diseased group will be compared to the control.
Study: NCT03536234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin acetate depot
Description: 3.75 mg triptorelin depot (monthly injections). 3 doses in total